We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




New FISH Test Developed for Colorectal Cancer Detection

By LabMedica International staff writers
Posted on 23 Nov 2009
New tissue-based fluorescence in situ hybridization (FISH) technology is the first test developed for the detection of chromosomal anomalies associated with colon cancer. More...


"We are excited to be the first laboratory to offer GastroFISH for the colon. Using current histological techniques, identifying adenomas with a high risk for progression to cancer is not possible. Multitarget FISH will be helpful in the identification of these adenomas in conjunction with histology,” said Junqi Qian, M.D., director of molecular diagnostics at Bostwick Laboratories (Glen Allen, VA, USA).

GastroFISH, developed by Gastrocor (Glen Allen, VA, USA), is a diagnostic test with a high sensitivity and specificity that will aid in the differential diagnosis of adenoma from adenocarcinoma. The results from GastroFISH, together with a pathology diagnosis, will assist the physician in guiding a more effective treatment plan for the patient.

Related Links:

Gastrocor


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Hemodynamic System Monitor
OptoMonitor
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The partnership with LLS expands access to Lucent’s non-invasive blood-based biomarker tests for early detection of cognitive diseases (photo courtesy of Adobe Stock)

New Partnership Brings Alzheimer’s Blood Biomarker Test to Community Screening Network

Lucent Diagnostics, a brand of Quanterix Corporation, has partnered with Life Line Screening (LLS) to offer Lucent’s non‑invasive, blood‑based biomarker test across the United States. Programs are... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.